Financial News
Latest News about LCTX
Recent news which mentions LCTX
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
November 02, 2022
From Benzinga
121 Stocks That Hit Their 52-Week Low
October 14, 2022
From Benzinga
A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
October 13, 2022
From Benzinga
EXCLUSIVE: Lineage Cell Establishes New R&D Facility In US, Expands Israel-Based Facility
October 03, 2022
From Benzinga
The Three Best Anti-Aging Stocks to Buy in September
September 19, 2022
From InvestorPlace
Lineage Cell Therapeutics Earnings Perspective: Return On Capital Employed
September 07, 2022
Tickers
LCTX
From Benzinga
Tickers
LCTX
From Motley Fool
From Benzinga
From Benzinga
Tickers
LCTX
From Motley Fool
From Benzinga
From Benzinga
Insiders Buying These 4 Penny Stocks
March 30, 2022
From Benzinga
Insiders Buy Over $1.3M Of 4 Penny Stocks
March 28, 2022
From Benzinga
Earnings Scheduled For March 10, 2022
March 10, 2022
From Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
March 06, 2022
From Benzinga
Stocks That Hit 52-Week Lows On Wednesday
February 23, 2022
From Benzinga
65 Biggest Movers From Yesterday
December 21, 2021
From Benzinga
Why Lineage Cell Therapeutics Zoomed Higher Today
December 20, 2021
From Motley Fool
38 Stocks Moving In Monday's Mid-Day Session
December 20, 2021
From Benzinga
Lineage, Genentech Ink Cell Therapy Licensing Pact For Ocular Diseases
December 20, 2021
From Benzinga
From InvestorPlace
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2021 Earnings Call Transcript
November 11, 2021
Tickers
LCTX
From Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
